Adrienne Graves, PhD, former CEO of Santen, opened this panel discussion by reiterating a sentiment expressed by surgeons, innovators, and investors: we’re in the middle of a glaucoma renaissance. The release of new devices, instruments, and pharmaceuticals has led to improvements in surgical procedures and other treatment options that promise to improve the lives of glaucoma patients.For this week’s discussion, originally recorded for the OIS Glaucoma Innovation Showcase, Dr. Graves corralled four ophthalmology leaders to discuss what’s new and what’s next in glaucoma innovation, how their companies stay resilient through the SARS-CoV-2 pandemic, and more.A glimpse: Jay Katz, MD, Chief Medical Officer of Glaukos, shared the latest news on the iDose® TR sustained-release travoprost implant and the iStent Infinite, an investigational device designed to reduce IOP in open-angle glaucoma patients.New World Medical, which focuses on glaucoma surgical devices, has three products launched and two in the pipeline. Santen,  developer of everything from drops to surgical solutions, is exploring new MOAs and preparing for Phase III clinical trials for PRESERFLO, a microshunt currently available in Europe and under FDA review. Allergan, part of AbbVie for a little over a year, has gotten DURYSTA, its biodegradable implant, into the hands of 2,000 physicians to date according to Ramin Valian.Listen to the full episode to hear the panel address the following:What would you like your company to focus on for glaucoma?How has COVID-19 affected your product development, marketing, and physician interactions?How are your companies part of the glaucoma solution?The podcast lineup includes:Adrienne Graves, PhD, former CEO of Santen (moderator)Jay Katz, MD, Chief Medical Officer, GlaukosBilal Khan, CEO of New World MedicalOmar Sadruddin, MD, Senior Medical Director of SantenRamin Valian, Vice President, Glaucoma, Surgical, Retina & Eye Care Portfolio-U.S., at Allergan, an AbbVie CompanyHit “Play” to Listen.